Key result
Intravenous administration of TAK-242-NP at reperfusion decreased infarct size in a mouse model of myocardial ischaemia-reperfusion injury, whereas TAK-242 solution did not.
Why the study?
Blockade of Toll-like receptor 4 in myocardial ischaemia-reperfusion injury has not been translated into clinical practice.
Does intravenous TAK-242-NP reduce infarct size in a mouse model of myocardial ischaemia-reperfusion injury?
Does intravenous TAK-242-NP reduce infarct size in a mouse model of myocardial ischaemia-reperfusion injury?
Nanoparticle-mediated delivery of the TLR4 inhibitor TAK-242 reduces myocardial infarct size in a mouse model of ischaemia-reperfusion injury by inhibiting monocyte-mediated inflammation.
Answers are grounded in this paper and cite their sources.
TAK-242-NP reduces infarct size at reperfusion in mice where free drug fails; leaves open translation to clinical ischaemia-reperfusion injury.
AIMS: Myocardial ischaemia-reperfusion (IR) injury hampers the therapeutic effect of revascularization in patients with acute myocardial infarction (AMI). Innate immunity for damage-associated protein patterns promotes the process of IR injury; however, the blockade of Toll-like receptor 4 (TLR4) in myocardial IR injury has not been translated into clinical practice. Therefore, we aimed to examine whether the nanoparticle-mediated administration of TAK-242, a chemical inhibitor of TLR4, attenuates myocardial IR injury in a clinically feasible protocol in a mouse model. METHODS AND RESULTS: We have prepared poly-(lactic-co-glycolic acid) nanoparticles containing TAK-242 (TAK-242-NP). TAK-242-NP significantly enhanced the drug delivery to monocytes/macrophages in the spleen, blood, and the heart in mice. Intravenous administration of TAK-242-NP (containing 1.0 or 3.0 mg/kg TAK-242) at the time of reperfusion decreased the infarct size, but the TAK-242 solution did not even when administered at a dosage of 10.0 mg/kg. TAK-242-NP inhibited the recruitment of Ly-6Chigh monocytes to the heart, which was accompanied by decreased circulating HMGB1, and NF-κB activation and cytokine expressions in the heart. TAK-242-NP did not decrease the infarct size further in TLR4-deficient mice, confirming the TLR4-specific mechanism in the effects of TAK-242-NP. Furthermore, TAK-242-NP did not decrease the infarct size further in CCR2-deficient mice, suggesting that monocyte/macrophage-mediated inflammation is the primary therapeutic target of TAK-242-NP. CONCLUSION: The nanoparticle-mediated delivery of TAK-242-NP represent a novel and clinical feasible strategy in patients undergone coronary revascularization for AMI by regulating TLR4-dependent monocytes/macrophages-mediated inflammation.
No takes yet. Share an insight, caveat, or question.
Fujiwara et al. (2019) studied Myocardial ischaemia-reperfusion injury. TAK-242-NP (nanoparticle-mediated administration of TAK-242) vs. TAK-242 solution was evaluated on Infarct size. Intravenous administration of TAK-242-NP at reperfusion decreased infarct size in a mouse model of myocardial ischaemia-reperfusion injury, whereas TAK-242 solution did not.
Synapse has enriched 10 related papers. Consider them for comparative context: